Author

C. Latimer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Assay:cryo-EM· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

S. S. McDade· 2 shared A. Bardelli· 1 shared A. G. Murzin· 1 shared A. Shah· 1 shared A. U. Lindner· 1 shared B. Ghetti· 1 shared C. Franco· 1 shared C. J. Scott· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. S. McDade

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tau filaments with the Alzheimer fold in cases with MAPT mutations V337M and R406W

C. Qi, S. Lovestam, A. G. Murzin, S. Peak-Chew, C. Franco, M. Bogdani, C. Latimer, J. R. Murrell, P. W. Cullinane, Z. Jaunmuktane, T. D. Bird, B. Ghetti, S. H. W. Scheres, M. Goedert

The paper determines the structures of tau filaments in individuals with MAPT mutations V337M and R406W using cryo-EM, finding the Alzheimer fold in all cases and a new triple filament assembly.

bioRxiv · Apr 29, 2024 · PreprintBiophysics

Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.

H. Khawaja, R. Briggs, C. Latimer, M. Rassel, D. Griffin, L. Hanson, A. Bardelli, F. Di Nicolantonio, S. S. McDade, C. J. Scott, S. Lambe, M. Maurya, A. U. Lindner, J. H. M. Prehn, J. Sousa, , S. Van Schaeybroeck

This study identifies Bcl-xL as a mediator of resistance to KRASG12C inhibitors in colorectal cancer and shows that combining Bcl-xL inhibition with KRASG12C inhibition enhances apoptosis and reduces tumor growth.

bioRxiv · May 10, 2022Cancer Biology

Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer

D. B. Longley, N. T. Crawford, K. J. Stott, T. Sessler, C. McCann, W. McDaid, C. Latimer, J. Fox, J. M. Munck, T. Smyth, A. Shah, V. Martins, M. Lawler, P. D. Dunne, E. M. Kerr, , V. M. Coyle

This study shows tolinapant, an IAP inhibitor, enhances chemotherapy-induced apoptosis in colorectal cancer by modulating FLIP and HDACs, suggesting its clinical use in poor prognosis MSS CRC with elevated cIAP1/2.

bioRxiv · Nov 20, 2020Cancer Biology